Corporate Milestones
2024
Materialise Expands Cardiovascular Capabilities through FEops Acquisition. Integration of FEops' AI-driven simulation with Materialise's 3D planning insights to advance mass personalization in cardiac care.
2024
Clinical utility of FEops AI-enabled predictive pre-planning for LAAO demonstrated in US. Data showing FEops HEARTguide significantly improves efficiency of LAAO procedures presented at the 2024 AF symposium.
2023
FEops Partners with TeraRecon to scale the commercialization of FEops HEARTguide, its Digital Twin Solution for an Elevated Structural Heart Experience.
2023
FEops Receives FDA Clearance for Its AI-Based Anatomical Analysis Capabilities.
2023
FEops HEARTguide Proven to Significantly Enhance Efficiency and Outcomes of LAA Closure Procedures.
2023
FEops Appoints Euan S. Thomson, PhD as Board Chair in Support of Expanding Digital Health Goals.
2022
FEops wins the ‘Prijs van de Vlaamse regering voor de Scale-Up van het Jaar’ 2022 – Scale-up of the Year 2022. This award is given to Flemish growth companies which have performed impressively during the past year.
2022
PREDICT-LAA clearly shows that FEops HEARTguide improves both efficiency and outcomes of LAA occlusion procedures.
2022
FEops HEARTguide receives FDA clearance for LAAo planning capabilities with Abbott's Amplatzer Amulet and Boston Scientific's Watchman FLX device.
2021
FEops Appoints Digital Health Expert Euan Thomson to its Board of Directors
2021
FEops HEARTguide authorized by FDA for unprecedented LAAo planning
2021
New FEops HEARTguide release combining digital twins and AI to revolutionize structural heart planning
2021
2500 patients modeled
2020
Approval for Australian market
2020
Flanders Innovation and Entrepreneurship (VLAIO) supports FEops’ research for innovative approaches based on artificial intelligence and machine learning techniques with a grant of EUR 0.5m.
2020
PREDICT-LAA enrolls first patient
2019
FEops awarded Euro 3.2 million grant from the European Innovation Council accelerator program
2019
FEops selected by Dassault Systèmes to join the 3DEXPERIENCE Lab
2019
FEops commercially available on the Canadian Market
2019
FEops HEARTguide wins CSI Highlight of the Year award
2019
FEops HEARTguideTM receives CE mark
2018
TAVIguide extends CE mark indications to bicuspid patients
2018
FEops elects Tom Fleming to its board of directors
2017
FEops closes EUR 6 million Series B financing, led by Valiance, and joined by existing investors Capricorn and PMV.
2016
Rob Michiels appointed chairman of the board of directors
2015
TAVIguide™ receives CE mark
2015
EUR 1.3 million received in Series A financing
2009
FEops is founded